One-Liner
A predictive score estimating the probability FDA will issue a National Priority Voucher for a given drug indication, for use by regulatory affairs directors and biotech hedge funds.
AI Thinking Process
FDA National Priority Voucher programme (Q1 2026) speeds reviews for selected sponsors. Non-voucher sponsors wait longer; PDUFA delay costs $3-15M/month for small biotechs. Regulatory affairs directors monitor FDA dockets manually with no data-driven probability estimate.
G008 frequency trap: a biotech needs this once per drug programme over multi-year periods. Per-use purchase ~$50-200K consulting equivalent. Weak subscription frequency (G064: one-time regulatory event = consulting not SaaS).
G085: biotech hedge funds (Baker Brothers, RA Capital, Avoro) track voucher-implications across 30-50 portfolio programmes. Each voucher call moves security price. Probability index as alt-data feed: $100K/year × 30 funds = $3M ARR. Plausible.
EvaluatePharma, GlobalData, Informa Citeline Pharma Intelligence run FDA signal feeds. Voucher-probability index is their adjacency — would add as feature within 6-12 months (G006). Moat only through primary-source data (advisory transcript NLP, ex-FDA panels).
45% conviction — below 50% painpoint threshold. TAM too small ($8M ARR ceiling with ~40 customers), feature-absorbable by Informa/GlobalData within 12 months. The voucher theme needs to be a feature inside Evaluate/GlobalData, not an independent product.
No third pivot available — upstream buyer is the biotech itself (reverts to G064 consulting engagement). TAM bound is structural not positional. Resurrection FAILED.
Kill Reason
Per-drug, per-submission event means this is consulting not SaaS (G064). Pivot to biotech hedge-fund alt-data subscription failed on TAM ceiling: approximately 40 biotech funds × $200K/year = $8M ARR ceiling. Informa/GlobalData could absorb this as a 6-12 month feature addition, and they have existing relationships with every likely customer.
Risk Analysis
Risk analysis available for latest engine ideas.
What do you think?
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.